Prostate cancer screening: Clinical applications and challenges

Urologic Oncology: Seminars and Original Investigations

Volumn 22, Issue 4, 2004, Pages 353-357

  Brawley, Otis W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; DRE; Overdiagnosis; PCPT; Prostate; PSA

Indexed keywords

FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

CANCER CENTER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; INFORMED CONSENT; MASS SCREENING; MEDICAL ETHICS; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PUBLIC HEALTH; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; TUMOR LOCALIZATION; UNITED KINGDOM; UNITED STATES;

ETHICS, MEDICAL; HUMANS; INFORMED CONSENT; MALE; MASS SCREENING; PATIENT CARE PLANNING; PATIENT EDUCATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 3342983363     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2004.04.014     Document Type: Conference Paper

References (23)

1. US Preventive Services Task Force. Screening for prostate cancer recommendation and rationale. Ann Intern Med. 137:2002;915-916
2. Kramer B.S., Brawley O.W. Cancer screening. Hematol Oncol Clin North Am. 14:2000;831-848
3. Gann P.H., Hennekens C.H., Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 273:1995;289-294
4. Bartsch G., Horninger W., Klocker H., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 58:2001;417-424
5. Shibata A., Ma J., Whittemore A.S. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst. 90:1998;1230-1231
6. Lu-Yao G., Albertsen P.C., Stanford J.L., Stukel T.A., Walker-Corkery E.S., Barry M.J. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 325:2002;740
7. Oliver S.E., May M.T., Gunnell D. International trends in prostate-cancer mortality in the "PSA ERA" Int J Cancer. 92:2001;893-898
8. Labrie F., Candas B., Dupont A., et al. Screening decreases prostate cancer death first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate. 38:1999;83-91
9. Boyle P. Screening for prostate cancer have you had your cholesterol measured? BJU Int. 92:2003;191-199
10. Alexander F.E., Prescott R.J. Reply to Labrie et al. Results of the mortality analysis of the Quebec Randomized/controlled trial (RCT). Prostate. 40:1999;135-137
11. Madalinska J.B., Essink-Bot M.L., de Koning H.J., Kirkels W.J., van der Maas P.J., Schroder F.H. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol. 19:2001;1619-1628
12. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 349:2003;215-224
13. Yao S.L., Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst. 94:2002;958-960
14. Etzioni R., Penson D.F., Legler J.M., et al. Overdiagnosis due to prostate-specific antigen screening lessons from U. S. prostate cancer incidence trends. J Natl Cancer Inst. 94:2002;981-990
15. DEVCAN. Feuer E.J., Wun L.M. Probability of Developing or Dying of Cancer Software, Version 5.0. 1999;National Cancer Institute, Washington, DC
16. Harris R., Lohr K.N. Screening for prostate cancer an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 137:2002;917-929
17. Smith R.A., Cokkinides V., Eyre H.J. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin. 53:2003;27-43
18. Reddy S., Shapiro M., Morton R. Jr, Brawley O.W. Prostate cancer in black and white Americans. Cancer Metastasis Rev. 22:2003;83-86
19. Bianco F.J. Jr, Wood D.P. Jr, Gringo D.J., Sakr W.A., Pontes J.E., Powell I.J. Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy. J Urol. 168:2002;479-482
20. Banerjee M., Powell I.J., George J., Biswas D., Bianco F., Severson R.K. Prostate specific antigen progression after radical prostatectomy in African-American men versus white men. Cancer. 94:2002;2577-2583
21. Brawley O.W. The study of untreated syphilis in the negro male. Int J Radiat Oncol Biol Phys. 40:1998;5-8
22. Brawley O.W. Prostate cancer and black men. Semin Urol Oncol. 16:1998;184-186
23. Bubolz T., Wasson J.H., Lu-Yao G., Barry M.J. l: Treatments for prostate cancer in older men: 1984-1997. Urology. 58:2001;977-982